search
Back to results

Aesthetic Performance and Tolerance of an Injective Intradermal Treatment for the Skin Roughness and Laxity of Back of the Hands

Primary Purpose

Skin Laxity, Skin Roughness

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Profhilo® Body
Sponsored by
IBSA Farmaceutici Italia Srl
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Skin Laxity focused on measuring Skin laxity, Skin roughness, Profhilo Body, Hyaluronic Acid, Hybrid Cooperative Complexes

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Will be included in the study volunteers with the following characteristics:

  • female and male sex, not necessarily 1:1 ratio;
  • age 18-65 years;
  • asking for hands restoration;
  • available and able to return to the study site for the post-procedural follow-up examinations;
  • accepting to not change their habits regarding food, physical activity, cosmetic and cleansing products for the hands;
  • accepting not to expose their hands to strong UV irradiation (UV session, or sun bathes) during the entire duration of the study, without appropriate sun protection;

Exclusion Criteria:

  • Pregnancy;
  • lactation;
  • smokers;
  • alcohol or drug abusers;
  • subjects not in menopause who do not use adequate contraceptive precautions in order to avoid pregnancies during the study;
  • Body Mass Index (BMI) variation (± 1) during the study period;
  • performing non-surgical skin aesthetic procedures for hands in the 6 months prior to the study start;
  • aesthetic surgical procedure for the hands in the past;
  • change in the normal habits regarding food, physical activity, cosmetic products and cleansing for the hands during the month preceding the test;
  • sensitivity to the test product or its ingredients (to be assessed by the investigator during the baseline visit);
  • subjects whose insufficient adhesion to the study protocol is foreseeable;
  • participation in a similar study currently or during the previous 6 months.)
  • presence of cutaneous disease on the tested area, as lesions, scars, malformations;
  • clinical and significant skin condition on the test area (e.g. active eczema, psoriasis, sclerodermia, local infections).

Exclusion criteria due to systemic disease:

  • Diabetes;
  • endocrine disease;
  • hepatic disorder;
  • renal disorder;
  • cardiac disorder;
  • pulmonary disease;
  • cancer;
  • neurological or psychological disease;
  • inflammatory/immunosuppressive disease;
  • drug allergy Exclusion criteria due to ongoing pharmacological treatment
  • Anticoagulants and antiplatelet drugs, anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago);
  • using of drugs able to influence the test results in the investigator opinion. The use of other drugs, not mentioned above, can be authorized by the Investigator. The trade name, the dosage, the start and stop date of the therapy will be reported on concomitant medication form.

Sites / Locations

  • DERMING S.r.l., Clinical Research and Bioengineering Institute

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Profhilo® Body treatment group

Arm Description

1.5 ml per hand injected by a blunt tip microcannula (25G or 22G, preferably 22G), with fanning technique through a single entry point performing 5 passages and injecting 0,3 ml per passage. Day 0: Information and consent form provided. Clinical photography, Clinical assessment, Instrumental assessment, First treatment of Profhilo® (refer to study protocol). Day 30 (1 month after day 0): Clinical photography, Clinical assessment, Instrumental assessment, Second treatment of Profhilo® (refer to study protocol), Self-evaluation questionnaire. Day 120 (4 months after day 0): Clinical photography, Clinical assessment, Instrumental assessment, NO treatment, Self-evaluation questionnaire.

Outcomes

Primary Outcome Measures

Change from Baseline of Skin Roughness and flaccidity at 30 days and at 120 days post-injection
Visual score from 1 (no roughness and flaccidity) to 5 (very severe roughness and flaccidity)
Change from Baseline of Skin density (profilometry) at 30 days and at 120 days post-injection
A picture of the skin is taken thanks to Primos compact portable device (GFMesstechnik) and a 3D representation is elaborated by Primos software.
Change from Baseline of Superficial and deep skin plastoelasticity at 30 days and at 120 days post-injection
Measurement of the principal torsiometric parameters Ue (immediate extensibility), Uf (final extensibility), Uv (viscoelasticity) and Ur (immediate elastic recovery) by the instrument Dermal Torque Meter (Dia-Stron Ltd., UK)
Change from Baseline of Tissue dielectric constant value of superficial and deep skin layers at 30 days and at 120 days post-injection
Non-invasive measurements of dielectric constant of the skin and subcutaneous fat by MoistureMeterD (Delfin Technologies, Kuopio - Finland). MoistureMeterD measures the changes in the total water content in the tissue with 0.5mm and 1.5mm probes.
Change from Baseline of Photographic evaluation at 30 days and at 120 days post-injection
2D pictures of the dorsum of both hands are taken in order to support the aesthetic result assessment

Secondary Outcome Measures

Efficacy questionnaire
Self-assessment questionnaire regarding skin roughness and laxity of the treated areas, skin suppleness, skin smoothness, skin hydration, skin lifting, contour redefinition/remodeling (score: very marked; marked; medium; light; absent)
Treatment tolerance questionnaire
Self-assessment score: bad; poor; good; excellent

Full Information

First Posted
September 27, 2022
Last Updated
September 27, 2023
Sponsor
IBSA Farmaceutici Italia Srl
Collaborators
Derming SRL
search

1. Study Identification

Unique Protocol Identification Number
NCT05590364
Brief Title
Aesthetic Performance and Tolerance of an Injective Intradermal Treatment for the Skin Roughness and Laxity of Back of the Hands
Official Title
Interventional, Post-marketing, Local, Mono-centric Study for Evaluation of Aesthetic Performance and Tolerance of an Injective Intradermal Treatment for the Skin Roughness and Laxity of Back of the Hands
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
November 7, 2022 (Actual)
Primary Completion Date
June 8, 2023 (Actual)
Study Completion Date
June 8, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
IBSA Farmaceutici Italia Srl
Collaborators
Derming SRL

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
People lose collagen all over the body, not just in the face; skin roughness and laxity of the dorsum of the hands can result from chrono and photo-aging. This skin roughness and laxity can range from very mild to severe; injection procedures can provide new tone and firmness to the skin of the hand dorsum. Dermal fillers are the most used non-permanent injectable materials available today to correct skin flaccidity and roughness on the dorsum of the hands. They give immediate aesthetic effect due to elastic gel matrix injected and impart longer term effects due to bio stimulation, promoting new collagen formation. The objective of this study is to investigate the aesthetic performance of the Hyaluronic acid (HA)- based dermal filler Profhilo® Body injected by a blunt tip microcannula (25G or 22G, preferably 22G), with fanning technique through a single entry point performing 5 passages and injecting 0,3 ml per passage, 1,5 ml for each hand. Volunteers of both sexes, aged 18-65 years with mild-moderate skin roughness and laxity at the level of hand dorsum are to be treated.
Detailed Description
Open, monocentric. 3 visits, 55 subjects. Primary endpoint of the study is the evaluation of performance and tolerance of Profhilo Body (3ml) treatment in the back of the hands ( or dorsum of the hands). Secondary endpoint is self-assessment questionnaire by both doctors and volunteers. Profhilo® Body (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 3.25 ml non-pyrogenic pre-filled syringe, containing 3 ml of 3.2% hyaluronic acid for intradermal use (48 mg H-HA + 48 mg L-HA) dissolved in 3 ml of saline buffered sodium chloride. - IBSA Farmaceutici Italia S.r.l. - ITALY. The principle component is cross-linked Hyaluronic Acid of non-animal origin, produced by bacterial fermentation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Skin Laxity, Skin Roughness
Keywords
Skin laxity, Skin roughness, Profhilo Body, Hyaluronic Acid, Hybrid Cooperative Complexes

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
55 subjects undergoing Profhilo Body treatment in the back of the hands, 3 visits: Day 0 (treatment) Day 30 (1 month after Day 0 treatment) Day 120 (4 months after Day 0 - follow-up).
Masking
None (Open Label)
Masking Description
No masking
Allocation
N/A
Enrollment
51 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Profhilo® Body treatment group
Arm Type
Experimental
Arm Description
1.5 ml per hand injected by a blunt tip microcannula (25G or 22G, preferably 22G), with fanning technique through a single entry point performing 5 passages and injecting 0,3 ml per passage. Day 0: Information and consent form provided. Clinical photography, Clinical assessment, Instrumental assessment, First treatment of Profhilo® (refer to study protocol). Day 30 (1 month after day 0): Clinical photography, Clinical assessment, Instrumental assessment, Second treatment of Profhilo® (refer to study protocol), Self-evaluation questionnaire. Day 120 (4 months after day 0): Clinical photography, Clinical assessment, Instrumental assessment, NO treatment, Self-evaluation questionnaire.
Intervention Type
Device
Intervention Name(s)
Profhilo® Body
Intervention Description
Dosage form: Profhilo® Body (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 3.25 ml non-pyrogenic pre-filled syringe, containing 3 ml of 3.2% hyaluronic acid for intradermal use (48 mg H-HA + 48 mg L-HA) dissolved in 3 ml of saline buffered sodium chloride.
Primary Outcome Measure Information:
Title
Change from Baseline of Skin Roughness and flaccidity at 30 days and at 120 days post-injection
Description
Visual score from 1 (no roughness and flaccidity) to 5 (very severe roughness and flaccidity)
Time Frame
Day 0, Day 30, Day 120
Title
Change from Baseline of Skin density (profilometry) at 30 days and at 120 days post-injection
Description
A picture of the skin is taken thanks to Primos compact portable device (GFMesstechnik) and a 3D representation is elaborated by Primos software.
Time Frame
Day 0, Day 30, Day 120
Title
Change from Baseline of Superficial and deep skin plastoelasticity at 30 days and at 120 days post-injection
Description
Measurement of the principal torsiometric parameters Ue (immediate extensibility), Uf (final extensibility), Uv (viscoelasticity) and Ur (immediate elastic recovery) by the instrument Dermal Torque Meter (Dia-Stron Ltd., UK)
Time Frame
Day 0, Day 30, Day 120
Title
Change from Baseline of Tissue dielectric constant value of superficial and deep skin layers at 30 days and at 120 days post-injection
Description
Non-invasive measurements of dielectric constant of the skin and subcutaneous fat by MoistureMeterD (Delfin Technologies, Kuopio - Finland). MoistureMeterD measures the changes in the total water content in the tissue with 0.5mm and 1.5mm probes.
Time Frame
Day 0, Day 30, Day 120
Title
Change from Baseline of Photographic evaluation at 30 days and at 120 days post-injection
Description
2D pictures of the dorsum of both hands are taken in order to support the aesthetic result assessment
Time Frame
Day 0, Day 30, Day 120
Secondary Outcome Measure Information:
Title
Efficacy questionnaire
Description
Self-assessment questionnaire regarding skin roughness and laxity of the treated areas, skin suppleness, skin smoothness, skin hydration, skin lifting, contour redefinition/remodeling (score: very marked; marked; medium; light; absent)
Time Frame
Day 30, Day 120
Title
Treatment tolerance questionnaire
Description
Self-assessment score: bad; poor; good; excellent
Time Frame
Day 30, Day 120

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Will be included in the study volunteers with the following characteristics: female and male sex, not necessarily 1:1 ratio; age 18-65 years; asking for hands restoration; available and able to return to the study site for the post-procedural follow-up examinations; accepting to not change their habits regarding food, physical activity, cosmetic and cleansing products for the hands; accepting not to expose their hands to strong UV irradiation (UV session, or sun bathes) during the entire duration of the study, without appropriate sun protection; Exclusion Criteria: Pregnancy; lactation; smokers; alcohol or drug abusers; subjects not in menopause who do not use adequate contraceptive precautions in order to avoid pregnancies during the study; Body Mass Index (BMI) variation (± 1) during the study period; performing non-surgical skin aesthetic procedures for hands in the 6 months prior to the study start; aesthetic surgical procedure for the hands in the past; change in the normal habits regarding food, physical activity, cosmetic products and cleansing for the hands during the month preceding the test; sensitivity to the test product or its ingredients (to be assessed by the investigator during the baseline visit); subjects whose insufficient adhesion to the study protocol is foreseeable; participation in a similar study currently or during the previous 6 months.) presence of cutaneous disease on the tested area, as lesions, scars, malformations; clinical and significant skin condition on the test area (e.g. active eczema, psoriasis, sclerodermia, local infections). Exclusion criteria due to systemic disease: Diabetes; endocrine disease; hepatic disorder; renal disorder; cardiac disorder; pulmonary disease; cancer; neurological or psychological disease; inflammatory/immunosuppressive disease; drug allergy Exclusion criteria due to ongoing pharmacological treatment Anticoagulants and antiplatelet drugs, anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago); using of drugs able to influence the test results in the investigator opinion. The use of other drugs, not mentioned above, can be authorized by the Investigator. The trade name, the dosage, the start and stop date of the therapy will be reported on concomitant medication form.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Adele Sparavigna, MD
Organizational Affiliation
DERMING S.r.l., Clinical Research and Bioengineering Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
DERMING S.r.l., Clinical Research and Bioengineering Institute
City
Milano
State/Province
Lombardia
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Aesthetic Performance and Tolerance of an Injective Intradermal Treatment for the Skin Roughness and Laxity of Back of the Hands

We'll reach out to this number within 24 hrs